Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 75%
filed 2026-07-15
EX-99.1
NewcelX announced the grant of a Brazilian patent (BR 112018010946-0) for its NCEL-101 cell selection and enrichment technology, protecting the manufacturing process until November 2036. While this is a positive intellectual property milestone that strengthens the company's global IP portfolio and supports future partnering opportunities, it is primarily an operational/strategic development rather than a discrete material event in the traditional 8-K taxonomy. The patent grant itself is not a financial event (debt, equity, M&A), governance event, or existential threat. However, it is material to investors as it enhances the company's competitive position and IP protection in a strategically important market (Brazil, with ~500,000 T1D patients), particularly in the context of the company's recent FDA Type B Pre-IND meeting success for NCEL-101.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-07-15
EX-99.1
This is a press release dated July 15, 2026, announcing Karooooo Ltd.'s first quarter 2027 unaudited financial results. The document discloses quarterly revenue (ZAR1,354 million subscription revenue, 19% Y/Y growth), operating profit (ZAR410 million, 16% growth), earnings per share (ZAR9.53, 11% growth), and key operational metrics (2.8 million subscribers, 142,472 net additions). The company also reaffirms FY27 guidance for subscription revenue growth and 21% EPS growth. This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-15
EX-99.1
This press release announces the initiation of a Phase IIb clinical trial for SCI-110 at Hannover Medical School in Germany, representing a material advancement in SciSparc's drug development pipeline for Tourette Syndrome. The disclosure describes a significant operational and clinical milestone—progression from Phase IIa to Phase IIb with positive prior safety and efficacy data (21% average tic reduction)—that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects, but does not fit the discrete event categories of earnings release, M&A, executive changes, or other named types.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-15
EX-99.1
This exhibit is an Amended and Restated 2012 Share Option Plan for PolyPid Ltd., which establishes the terms, administration, and mechanics of equity compensation for employees, officers, directors, and service providers. The document sets forth vesting schedules, exercise prices, and other material terms of option grants. As a plan amendment affecting compensatory arrangements for multiple classes of participants, this constitutes a disclosure of executive and employee compensation arrangements that would be material to a reasonable investor's assessment of the company's capital structure and incentive practices.
View raw filing on EDGAR →
6-K
Exec departure
confidence 75%
filed 2026-07-15
Mr. Shibin Yu resigned as Chief Financial Officer and director of ATIF Holdings on July 14, 2026, effective immediately. While the filing also discloses the appointment of Dr. Kamran Khan as interim CFO, the principal disclosed action is Yu's departure from both the CFO and board positions. The resignation of a CFO is material to investors' assessment of the company's financial leadership and governance.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-07-15
The 6-K discloses the closing of a patent acquisition by the Company's subsidiary Shuhai Tianjin from Tianjin Qianli Culture Media Co., Ltd. on June 23, 2026, for RMB 7.0 million in consideration, with 1,122,156 restricted Class A ordinary shares issued at US$0.9156 per share. This constitutes a material acquisition transaction that would affect a reasonable investor's assessment of the registrant's asset base and strategic direction in AI technology.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-15
Item 8.01
The filing discloses a Nasdaq minimum bid price compliance issue under Listing Rule 5550(a)(2), which is a delisting risk event. Although the Company ultimately regained compliance by July 10, 2026, the disclosure centers on the notice of non-compliance received on January 29, 2026, and the subsequent resolution. This is a material event affecting continued listing status and would be of significant concern to investors, even though the immediate delisting threat has been resolved.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-15
The filing discloses under Item 7.01 (Regulation FD Disclosure) the availability of a corporate investor presentation detailing the company's development of Bisphosphocin® compounds, lead program Nu-3 for infected diabetic foot ulcers, clinical trial design, regulatory strategy, and upcoming Phase 2 milestones. This is a strategic operational disclosure of clinical development progress and pipeline advancement rather than a routine administrative matter, making it material to investors assessing the company's drug development trajectory and competitive position.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-07-15
Item 8.01
This disclosure concerns a one-month extension of Ribbon Acquisition Corp.'s deadline to consummate an initial business combination, funded by a $125,000 deposit into the trust account. While the extension itself is a governance/procedural matter related to the SPAC's timeline obligations, it signals that the company has not yet completed its business combination and is exercising contractual extension rights. This is material to shareholders as it affects the timeline for the SPAC's fundamental purpose and the potential return of capital if no combination is consummated.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-15
The 6-K discloses the appointment of Mr. Ning Xue as an independent director effective July 14, 2026, along with his appointment as Chairperson of the Nominating and Corporate Governance Committee and member of the Audit and Compensation Committees. While Dr. Jiayuan Tong's resignation is also mentioned, the principal disclosed action is the appointment of a new director to fill the vacancy, making this an exec_appointment event. The appointment includes detailed background on Mr. Xue's qualifications and compensation terms ($14,082 for the initial term).
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-15
Item 7.01
LQR House Inc. implemented a 1-for-100 reverse stock split effective July 13, 2026, to regain compliance with Nasdaq's $1.00 minimum closing price requirement for continued listing. The company disclosed this delisting-risk mitigation measure via press release on July 15, 2026.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-15
Item 1.01
Palmer Square Capital BDC Inc. completed a $300 million CLO refinancing on July 15, 2026, issuing $228 million of AAA Class A-R Notes and $72 million of AA Class B-R Notes due 2039 pursuant to an amended indenture. This represents the creation of new direct financial obligations backed by a diversified portfolio of senior secured loans, constituting a material debt issuance under Item 1.01.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 97%
filed 2026-07-15
Item 2.03
Fermi Inc. completed an upsized offering of $431.25 million aggregate principal amount of 5.00% Convertible Senior Notes due 2031, with net proceeds of approximately $416.81 million. The convertible notes were issued to Initial Purchasers under Section 4(a)(2) and Rule 144A exemptions and are convertible into up to 58,913,925 shares of common stock at an initial conversion price of approximately $9.52 per share. The company also entered into capped call transactions to mitigate dilution to existing shareholders.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-15
EX-99.1
Zhibao Technology received a Nasdaq deficiency letter for failure to maintain the Minimum Bid Price Requirement (Rule 5550(a)(2)), with closing bid prices below $1.00 per share from May 27 to July 9, 2026. The Company has 180 calendar days until January 6, 2027 to regain compliance, and if it fails to do so, "the Company's Class A ordinary shares will be subject to delisting." This is a material disclosure of delisting risk under Item 3.01 equivalent, as it directly threatens the registrant's continued listing status on Nasdaq.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-15
Item 3.01
The filing discloses a notice from the Nasdaq Hearings Panel granting Triller an exception to regain compliance with the Nasdaq Bid Price Rule (Rule 5550(a)(2)) by July 30, 2026. This is a continued listing compliance matter: the Company must achieve a closing bid price of $1.00 or more for twenty consecutive business days or face delisting. The disclosure explicitly references prior delisting proceedings and a remanded matter, establishing material delisting risk under Item 3.01.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-15
Item 1.01
Item 1.01 discloses entry into a material definitive agreement—specifically the underwriting agreement and related agreements governing the IPO of Samos Energy Acquisition Corporation. While technically an IPO is a capital-raising event rather than a traditional M&A transaction, the Item 1.01 caption and the filing's structure treat this as a material agreement entry. However, the core event is the completion of a $230 million IPO with warrant issuances, which is more accurately characterized as a dilutive equity issuance and capital formation event. The Item 3.02 disclosure of the private placement warrants ($6 million) further supports classification as dilutive_issuance, but Item 1.01's explicit framing as "Entry into a Material Definitive Agreement" and the multiple binding agreements (underwriting, warrant, trust, registration rights, etc.) entered into on July 10, 2026, suggest the filing's primary intent is to disclose material contractual commitments. Given the ambiguity between ma_activity (which typically covers M&A) and dilutive_issuance (which covers unregistered equity sales), and the fact that Item 1.01 is the lead item, ma_activity is the most defensible classification, though dilutive_issuance would also be reasonable for the private placement warrant component.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-15
EX-99.1
The press release announces the appointment of Rodrigo Natale as Chief Financial Officer of Nuvini Group Limited, effective July 20, 2026. This is a clear executive appointment of a named officer to a senior leadership role. The appointment is material because it fills a CFO vacancy that had existed since February 2026 (when Roberto Otero resigned) and restores dedicated financial oversight and governance to the company.
View raw filing on EDGAR →
6-K
Governance Other
confidence 90%
filed 2026-07-15
EX-99.1
SOS Ltd is soliciting shareholder votes on eight proposals at an Extraordinary General Meeting scheduled for July 27, 2026, including a comprehensive share capital reduction and reorganization (reducing par value from US$0.75 to US$0.0000001 per share), share consolidation authorization (1-for-2 to 1-for-20 ratio), adoption of amended memoranda and articles of association, and approval of a 2026 equity incentive plan. These governance matters would materially affect the company's capital structure and shareholder rights.
View raw filing on EDGAR →
6-K
Earnings release
confidence 85%
filed 2026-07-15
EX-99.1
This exhibit is a sales update press release announcing FY26 financial results for Immuron's Travelan® product across multiple geographic markets (Global, Australia, Canada, USA). The document discloses unaudited sales figures for the full fiscal year and quarterly periods, demonstrating "four consecutive quarters of growth over prior year." While labeled a "sales update" rather than a full earnings release, it presents material financial performance metrics that would affect a reasonable investor's assessment of the company's commercial progress and revenue trajectory.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-15
EX-99.2
Wetour Robotics is soliciting shareholder approval for extraordinary governance changes including a massive increase in authorized share capital (from US$100,000 to US$20,000,000,000), a dual-class share reorganization creating Class A and Class B shares with differential voting rights (100:1 ratio favoring insiders Micava Co., Ltd. and Annan Tech Co., Ltd.), and authorization for future share consolidations up to 250:1.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-07-15
EX-99.1
This is a news release disclosing Q1 Fiscal 2027 operational and production results for Silvercorp Metals, including revenue of $138.7 million (up 70% YoY), detailed production figures for silver, gold, lead, and zinc across operating mines, and exploration/development progress. The release announces the timing of the full unaudited interim financial results (August 10, 2026). While styled as an operational update rather than a formal earnings press release, it discloses material quarterly financial and operational metrics that would affect investor assessment of the company's performance and is the functional equivalent of an earnings announcement.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 98%
filed 2026-07-15
EX-99.1
This exhibit discloses the results of Sigma Lithium's 2026 Annual Meeting of Shareholders held on June 30, 2026, including the election of all five director nominees (Ana Cristina Cabral re-elected with 97.41%, Marcelo Paiva with 83.97%, Junaid Jafar with 99.94%, Alexandre Rodrigues Cabral with 99.94%, and Kátia Abreu with 99.97%) and approval of the auditor appointment (Grant Thornton LLP with 99.95% support). The disclosure includes detailed voting tallies and percentages, which is the hallmark of shareholder vote results disclosure. This is material as it confirms board composition and auditor appointment for the ensuing year.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 98%
filed 2026-07-15
EX-99.1
This exhibit discloses the voting results from Sigma Lithium's Annual and Special Meeting of Shareholders held June 30, 2026, including shareholder approval of fixing the board at five directors, election of five named directors (Ana Cristina Cabral, Marcelo Paiva, Junaid Jafar, Alexandre Rodrigues Cabral, and Kátia Abreu), and appointment of Grant Thornton Auditores Independentes Ltda. as auditors. The disclosure explicitly states it is furnished "in accordance with Section 11.3 of National Instrument 51-102," confirming this is a formal shareholder vote results disclosure material to investors' understanding of corporate governance.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-15
AXIA Energia completed the sale of its 49% minority equity interests in four special purpose entities engaged in electric power transmission to GEBBRAS Participações Ltda. for BRL 451.4 million on July 15, 2026. This is a material disposition of significant assets (transmission lines spanning ~1,086 km across six Brazilian states) that affects the registrant's capital structure and strategic positioning, warranting classification as a completed M&A activity under Item 1.02 equivalent disclosure.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-15
The Board of Directors approved an update to the Company's optimal capital structure parameters and Dividend Policy, adjusting financial leverage targets from 2.8x to 2.9x net debt/EBITDA and extending convergence timelines from 24 to 48 months. This is a material governance and capital allocation decision affecting shareholder returns and financial strategy, disclosed as a Board-approved policy change rather than a discrete operational or financial event.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-15
The 6-K furnishes minutes of the 276th Board of Directors meeting held July 15, 2026, in which the Board unanimously approved an amendment to the Company's Dividend Policy, updating parameters for dividend distribution in line with the Company's optimal capital structure. This is a governance action (board deliberation and policy amendment) that would affect investor expectations regarding future dividend distributions, making it material to shareholders.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-07-15
Item 2.02
Home Bancshares released Q2 2026 quarterly earnings, reporting net income of $119.3 million, record total revenue of $295.1 million, and adjusted net income of $128.1 million, with comprehensive financial metrics and operational highlights.
View raw filing on EDGAR →
6-K
Auditor Change
confidence 98%
filed 2026-07-15
The 6-K discloses that KPMG LLP declined reappointment as Westport's independent registered public accounting firm on May 7, 2026, and that Deloitte LLP was appointed as the successor auditor effective June 30, 2026, following shareholder approval. The filing explicitly states there were no disagreements, adverse opinions, or reportable events associated with KPMG's departure, and no prior consultations with Deloitte on accounting matters. This is a clear auditor change requiring disclosure under Item 4.01 of Form 8-K (or the 6-K equivalent).
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-07-15
Item 2.03
TVA entered into a Third Amended and Restated $1,000,000,000 credit facility on July 10, 2026, creating a new direct financial obligation with a five-year term through July 2031. This revolving credit agreement represents a material increase in borrowing capacity and liquidity that affects the registrant's capital structure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-07-15
Item 2.02
BNY Mellon disclosed its second quarter 2026 financial results on July 15, 2026, reporting diluted EPS of $2.45, total revenue of $5.7 billion (up 13% year-over-year), net income of $1.792 billion, and a pre-tax operating margin of 39.8%. The earnings release with detailed financial statements, segment performance, and management commentary is attached as Exhibit 99.1.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-07-15
EX-99.1
This is a company announcement disclosing net sales of DARZALEX for Q2 2026 (USD 4,207 million), which represents a material financial result. Although Genmab receives royalties rather than direct product sales, the announcement of quarterly product sales figures is a standard earnings disclosure that would affect a reasonable investor's assessment of the company's financial performance and royalty revenue stream.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-15
Item 2.02
Invesco Mortgage Capital Inc. declared a monthly cash dividend of $0.12 per share of common stock for July 2026, payable on August 14, 2026, with an ex-dividend date of July 27, 2026. The announcement includes preliminary financial data as of June 30, 2026, including book value, portfolio composition, and leverage metrics.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-15
Item 2.02
This is a clear earnings release disclosing Plumas Bancorp's financial results for Q2 2026 and the first half of 2026. The press release (Exhibit 99.1) reports record second quarter earnings of $9.9 million or $1.43 per share, up from $6.3 million or $1.07 per share in Q2 2025, along with detailed financial metrics including net interest income, return on assets, and balance sheet highlights. This is a material disclosure affecting investor assessment of the registrant's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-15
Item 2.02
Rekor Systems disclosed preliminary, unaudited financial results for Q2 2026, reporting revenue of $12.6 million, adjusted gross margin of 55%, adjusted EBITDA loss of $1.3 million, and quarter-end cash of $10 million, demonstrating material operational improvements from cost-reduction initiatives.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-15
Item 2.02
LCNB Corp. issued a press release on July 15, 2026 announcing financial results for the three and six months ended June 30, 2026, disclosing record quarterly net income of $7.5 million, earnings per share of $0.53 (up 29% year-over-year), and record net interest income of $19.8 million.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-15
Item 2.02
This is a straightforward earnings release disclosing J.B. Hunt's Q2 2026 financial results. The filing explicitly states "On July 15, 2026, we issued a news release announcing our revenues and earnings for the second quarter ended June 30, 2026," with the press release attached as Exhibit 99.1. The release reports Q2 2026 revenue of $3.50 billion (up 19%), operating income of $259.5 million (up 32%), and diluted EPS of $1.91 (up 45%), along with detailed segment performance and six-month results. This is a material disclosure affecting investor assessment of the registrant's financial performance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-15
Item 3.01
SPAR Group received a definitive delisting notice from Nasdaq on July 14, 2026, determining that the Corporation failed to comply with Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule) and Rule 5550(b) (Stockholders' Equity Rule), with delisting effective July 23, 2026, unless the Corporation requests an appeal by July 21, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-15
Item 5.07
At a Special Meeting of Stockholders held on July 10, 2026, shareholders voted on a reverse stock split (1:5 ratio) and an adjournment proposal; both proposals failed to receive majority approval, with the reverse stock split receiving 4,851,288 votes for versus 9,373,945 against.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-15
Item 1.01
Autonomix Medical entered into a warrant inducement agreement whereby it issued unregistered Series D-1 and Series D-2 warrants (collectively to purchase 857,462 shares) in exchange for the investor's exercise of existing warrants, generating approximately $2.6 million in gross proceeds. The new warrants were issued pursuant to Section 4(a)(2) exemption as a private placement of unregistered equity securities, diluting existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-15
Item 3.02
Cathay Precision closed an unregistered private placement of 3,470 shares of Series C-3 Convertible Preferred Stock for $3.47 million pursuant to Securities Purchase Agreements dated February 6 and March 9, 2026. The preferred stock is convertible into common stock at $0.632 per share, creating significant dilution to existing common shareholders upon conversion.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-15
Item 1.01
NextPlat Corp entered into a Membership Interest Purchase Agreement on July 14, 2026, to acquire 100% of Scott's Pharmacy, LLC for $1.5 million in cash. The acquisition is expected to close in Q4 2026 and will add approximately $5.6 million in profitable annual revenue while expanding the PharmcoRx retail footprint into the Pensacola, Florida market.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-15
Item 3.02
ASP Isotopes entered into exchange agreements whereby holders of approximately $109.2 million in QLE convertible notes will exchange their debt for approximately 23.2 million shares of ASPI common stock, representing approximately 17.8% of outstanding shares. This material unregistered equity issuance, conducted under Section 4(a)(2) and Regulation D exemptions, significantly dilutes existing shareholders and restructures the company's capital.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-15
Item 7.01
The filing announces the appointment of Michael Deal as Senior Vice President and Chief Operating Officer of Hycroft Mining, effective August 24, 2026. The press release (Exhibit 99.1) emphasizes his 20+ years of operating and technical leadership experience in gold and silver mining operations, his prior role at First Majestic Silver managing a $1 billion acquisition integration, and his direct relevance to Hycroft's strategy of advancing the Hycroft Mine. This is a material executive appointment to a senior operational leadership position.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-15
Item 8.01
Kairos Pharma disclosed interim safety data from an ongoing Phase 1 clinical trial of ENV-105 (Carotuximab) in combination with osimertinib for EGFR-mutated lung cancer. The press release highlights a "clean safety profile" with zero Grade 3+ toxicities in 13 patients, representing a material clinical milestone for the company's lead program. This is a clinical development milestone—a key operational and strategic event for a clinical-stage biopharmaceutical company—rather than a financial result, M&A activity, or governance matter. While clinical trial data disclosures are common for biotech firms, the characterization as "breakthrough" interim safety data and the emphasis on advancing toward efficacy readout make this material to investors assessing the registrant's pipeline progress and value.
View raw filing on EDGAR →
6-K
Other material
confidence 65%
filed 2026-07-15
EX-99.1
This press release discloses multiple material events bundled together: (1) workforce reduction with ~$0.4M restructuring costs, (2) scaling back of brokerage operations, (3) a $1.2M Series C preferred share issuance, and (4) a prior $2.5M loan refinancing. While workforce_reduction and dilutive_issuance are individually identifiable, the exhibit's primary framing emphasizes a comprehensive strategic transformation and restructuring. The disclosure does not fit cleanly into a single event type—it is a multi-faceted operational and financial restructuring announcement that would materially affect investor assessment of the company's strategic direction and financial position.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-15
EX-99.1
The exhibit discloses that Nasdaq has granted Cheche Group Inc. an additional 180-day extension to regain compliance with the minimum bid price rule (US$1.00 per share), with a new compliance deadline of January 11, 2027. The filing explicitly states: "If the Company does not regain compliance with the Rule by January 11, 2027, it may be subject to delisting from Nasdaq." This is a material delisting risk disclosure under Item 3.01 equivalent, as the company faces potential delisting if it fails to meet the bid price requirement within the extended period.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 75%
filed 2026-07-15
The filing discloses a Forbearance Agreement entered into on July 10, 2026, relating to two convertible promissory notes that "matured prior to the date of the Forbearance Agreement." The Company is restructuring $1,587,439.64 in outstanding debt into a 19-month payment plan with modified terms, indicating the original notes were in default or at imminent risk of default. While Item 1.01 frames this as entry into a material agreement and Item 2.03 addresses the financial obligation, the core event is a covenant breach or technical default on the matured notes that triggered the need for forbearance and loan modification—a classic early indicator of financial stress.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-15
EX-99.1
This exhibit announces the public launch of the TrainAlta Zebra Athletics eCommerce store, establishing a new standalone merchandise revenue channel for MMA.INC. The disclosure describes a strategic business expansion—separating gear sales from training programs, implementing vendor-direct fulfillment, and creating commerce infrastructure intended to scale across the broader MMA.INC ecosystem (BJJLink, MixedMartialArts.com, XP Passport). While not a discrete M&A transaction, debt issuance, or workforce action, this represents a material operational and commercial milestone that would affect a reasonable investor's assessment of the company's revenue diversification and growth strategy.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-07-15
The filing discloses an amendment to an existing Line of Credit Agreement with Monaco Investment Partners II, LP that extends the maturity date from the original term to May 31, 2028. While this is technically an amendment to an existing credit facility rather than a new debt issuance, it represents a material modification of a direct financial obligation. Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation) are both cited, indicating the company views this as a material financial event affecting its debt obligations.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-15
Mark Murray resigned from the Board of Directors effective July 13, 2026, for personal reasons with no disagreement with the Company. Item 5.02(b) explicitly governs director departures. While the press release emphasizes Murray's valued contributions and the amicable nature of his departure, the core disclosed event is a director's resignation, making this an exec_departure classification. The filing is material as director changes affect governance and investor assessment of the company.
View raw filing on EDGAR →